Special Issue

New Tools for Precision and Personalized Treatment in Gastrointestinal Cancers 2.0

Message from the Guest Editors

Dear colleagues, In the last few years, we have faced many challenges in the treatment of gastrointestinal cancers. Starting from diagnosis, moving forward with new surgical techniques, and finishing with the most innovative medical therapies, the management of these tumors has changed profoundly. Moreover, the development of translational oncology nowadays allows a personalized treatment, based on molecular profiling and genetic tools. This Special Issue will focus upon the key innovative aspects in the diagnosis and the surgical and oncological treatment of gastrointestinal cancers.

Guest Editors

Dr. Michele Ghidini

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Dr. Niki Katsara-Antonakea

Medical Student at Charité-Universitätsmedizin Berlin, Germany; Doctorand in the Gynecology Department of Charité Virchow Klinikum, Berlin, Germany

Deadline for manuscript submissions

closed (30 November 2021)



Gastrointestinal Disorders

an Open Access Journal by MDPI

Impact Factor 0.8 CiteScore 1.2



mdpi.com/si/88472

Gastrointestinal Disorders
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
gastrointestdisord@mdpi.com

mdpi.com/journal/ gastrointestdisord





Gastrointestinal Disorders

an Open Access Journal by MDPI

Impact Factor 0.8 CiteScore 1.2



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Richard W. McCallum

- 1. Department of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
- 2. Department of Internal Medicine, Texas Tech University Medical Center, Paul L. Foster School of Medicine, El Paso, TX 79905, USA
- 3. School of Medicine, University of Queensland, Brisbane, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions; authors retain copyright.

High Visibility:

indexed within Scopus, ESCI (Web of Science), FSTA, and other databases.

Journal Rank:

CiteScore - Q2 (Immunology and Microbiology (miscellaneous))

